Contemporary management of muscle-invasive bladder cancer

References

• The World Cancer Report – the major findings. Cent. Eur. J. Public Health11(3), 177–179 (2003).
   PubMedGoogle Scholar
• Stewart BW. World Cancer Report 2003. IARC Press, Lyon, France (2004).
   Google Scholar
• Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin. Surg. Oncol.13(5), 291–298 (1997).
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin.62(1), 10–29 (2012).
   PubMed Web of Science ®Google Scholar
• Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer5(9), 713–725 (2005).
   PubMed Web of Science ®Google Scholar
• Stein JP, Skinner DG. Surgical atlas. Radical cystectomy. BJU Int.94(1), 197–221 (2004).
   Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today – a homogeneous series without neoadjuvant therapy. J. Clin. Oncol.21(4), 690–696 (2003).
   PubMed Web of Science ®Google Scholar
• Ghoneim MA, Abdel-Latif M, El-Mekresh M et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J. Urol.180(1), 121–127 (2008).
   PubMed Web of Science ®Google Scholar
• Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int.85(7), 817–823 (2000).
   PubMed Web of Science ®Google Scholar
• Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer107(10), 2368–2374 (2006).
   PubMed Web of Science ®Google Scholar
• Herr H, Lee C, Chang S, Lerner S. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J. Urol.171(5), 1823–1828; discussion 1827–1828 (2004).
   PubMed Web of Science ®Google Scholar
• Goossens-Laan CA, Gooiker GA, Van Gijn W et al. A systematic review and meta-analysis of the relationship between hospital/surgeon volume and outcome for radical cystectomy: an update for the ongoing debate. Eur. Urol.59(5), 775–783 (2011).
   PubMed Web of Science ®Google Scholar
• Styn NR, Montgomery JS, Wood DP et al. Matched comparison of robotic-assisted and open radical cystectomy. Urology79(6), 1303–1309 (2012).
   Web of Science ®Google Scholar
• Bloom HJ, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br. J. Urol.54(2), 136–151 (1982).
   PubMedGoogle Scholar
• Sell A, Jakobsen A, Nerstrom B, Sorensen BL, Steven K, Barlebo H. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand. J. Urol. Nephrol. Suppl.138, 193–201 (1991).
   PubMedGoogle Scholar
• Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J. Urol.131(6), 1069–1072 (1984).
   PubMed Web of Science ®Google Scholar
• Smith JA Jr, Crawford ED, Paradelo JC et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a Phase III intergroup study. J. Urol.157(3), 805–807; discussion 807–808 (1997).
   PubMed Web of Science ®Google Scholar
• Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br. J. Urol.67(6), 608–615 (1991).
   PubMedGoogle Scholar
• Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.14(11), 2901–2907 (1996).
   PubMed Web of Science ®Google Scholar
• Nanus DM, Bosl GJ. Systemic chemotherapy in the management of bladder cancer. Cancer Treat. Res.46, 143–158 (1989).
   Google Scholar
• Scher H, Herr H, Sternberg C et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br. J. Urol.64(3), 250–256 (1989).
   PubMedGoogle Scholar
• Advanced Bladder Cancer Overview Collaboration. Neoadjuvant cisplatin for advanced bladder cancer. Cochrane Database Syst. Rev. (2), CD001426 (2000).
   Google Scholar
• Rintala E, Hannisdahl E, Fossa SD, Hellsten S, Sander S. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand. J. Urol. Nephrol.27(3), 355–362 (1993).
   PubMed Web of Science ®Google Scholar
• Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet354(9178), 533–540 (1999).
   PubMed Web of Science ®Google Scholar
• Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol.29(16), 2171–2177 (2011).
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet361(9373), 1927–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med.349(9), 859–866 (2003).
   PubMed Web of Science ®Google Scholar
• Sherif A, Holmberg L, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur. Urol.45(3), 297–303 (2004).
   PubMed Web of Science ®Google Scholar
• Chang JS, Lara PN Jr, Pan CX. Progress in personalizing chemotherapy for bladder cancer. Adv. Urol.2012, 364919 (2012).
   Google Scholar
• Von Der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol.18(17), 3068–3077 (2000).
   PubMed Web of Science ®Google Scholar
• Lee CT, Madii R, Daignault S et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J. Urol.175(4), 1262–1267; discussion 1267 (2006).
   PubMed Web of Science ®Google Scholar
• Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol.155(2), 495–499; discussion 499–500 (1996).
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst. Rev. (2), CD006018 (2006).
   Google Scholar
• Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol.19(20), 4005–4013 (2001).
   PubMed Web of Science ®Google Scholar
• Svatek RS, Shariat SF, Lasky RE et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin. Cancer Res.16(17), 4461–4467 (2010).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.10(7), 1066–1073 (1992).
   PubMed Web of Science ®Google Scholar
• Von Der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev. Anticancer Ther.3(1), 11–19 (2003).
   PubMedGoogle Scholar
• Von Der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol.23(21), 4602–4608 (2005).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, De Mulder PH, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol.19(10), 2638–2646 (2001).
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Bajorin DF. Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor. Nat. Clin. Pract. Urol.5(9), 484–485 (2008).
   PubMedGoogle Scholar
• Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J. Urol.185(1), 72–78 (2011).
   PubMed Web of Science ®Google Scholar
• Fedeli U, Novara G, Galassi C et al. Population-based analyses of radical cystectomy and urinary diversion for bladder cancer in northern Italy. BJU Int.108(8 Pt 2), E266–E271 (2011).
   Google Scholar
• Gandour-Edwards R, Lara PN Jr, Folkins AK et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer95(5), 1009–1015 (2002).
   PubMed Web of Science ®Google Scholar
• Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann. Oncol.21(4), 815–819 (2010).
   PubMed Web of Science ®Google Scholar
• Stadler WM, Lerner SP, Groshen S et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol.29(25), 3443–3449 (2011).
   PubMed Web of Science ®Google Scholar
• Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J. Clin. Oncol.19(1), 89–93 (2001).
   PubMed Web of Science ®Google Scholar
• Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J. Clin. Oncol.16(4), 1298–1301 (1998).
   PubMed Web of Science ®Google Scholar
• Solsona E, Climent MA, Iborra I et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a Phase 2 nonrandomized comparative trial with radical cystectomy. Eur. Urol.55(4), 911–919 (2009).
   Google Scholar
• Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J. Clin. Oncol.20(14), 3061–3071 (2002).
   PubMed Web of Science ®Google Scholar
• Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N. Engl. J. Med.329(19), 1377–1382 (1993).
   PubMed Web of Science ®Google Scholar
• Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur. Urol.33(Suppl. 4), 32–34 (1998).
   Google Scholar
• Devere White RW, Lara PN Jr., Goldman B et al. A sequential treatment approach to myoinvasive urothelial cancer: a Phase II Southwest Oncology Group trial (S0219). J. Urol.181(6), 2476–2480; discussion 2480–2471 (2009).
   PubMed Web of Science ®Google Scholar
• Housset M, Maulard C, Chretien Y et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J. Clin. Oncol.11(11), 2150–2157 (1993).
   PubMed Web of Science ®Google Scholar
• Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer64(2), 131–139 (2009).
   Google Scholar
• Vilmar AC, Santoni-Rugiu E, Sorensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter Phase III trial. Ann. Oncol.21(9), 1817–1824 (2010).
   PubMed Web of Science ®Google Scholar
• Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol.24(29), 4731–4737 (2006).
   PubMed Web of Science ®Google Scholar
• Hoffmann AC, Wild P, Leicht C et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia12(8), 628–636 (2010).
   PubMed Web of Science ®Google Scholar
• Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI, Srinivas S. Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int.106(11), 1805–1811 (2010).
   PubMed Web of Science ®Google Scholar
• Matsumura N, Hara I. [The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy]. Hinyokika Kiyo57(3), 157–161 (2011).
   Google Scholar
• Takata R, Katagiri T, Kanehira M et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci.98(1), 113–117 (2007).
   PubMed Web of Science ®Google Scholar
• Williams PD, Cheon S, Havaleshko DM et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res.69(21), 8302–8309 (2009).
   PubMed Web of Science ®Google Scholar
• Vinall RL, Ripoll AZ, Wang S, Pan CX, Devere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int. J. Cancer130(11), 2526–2538 (2012).
   Google Scholar
• Smith SC, Havaleshko DM, Moon K et al. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia13(1), 72–80 (2011).
   PubMed Web of Science ®Google Scholar
• Henderson PT, Pan CX. Human microdosing for the prediction of patient response. Bioanalysis2(3), 373–376 (2010).
   PubMedGoogle Scholar
• Wang S, Zhang H, Malfatti M et al. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem. Res. Toxicol.23(11), 1653–1655 (2010).
   PubMed Web of Science ®Google Scholar
• Lin TY, Zhang H, Wang S et al. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol. Cancer10(1), 9 (2011).
   PubMedGoogle Scholar
• Zhang H, Aina OH, Lam KS et al. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol. Oncol. doi:10.1016/j.urolonc.2010.06.011 (2010) (Epub ahead of print).
   Google Scholar
• Lin T, Zhang H, Luo J et al. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int. J. Nanomed.7, 2793–2804 (2012).
   PubMed Web of Science ®Google Scholar